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Hepatocellular carcinomaAbstract Purpose: The purpose of this study was to assess the role of dynamic contrast enhanced
and diffusion MR imaging in the detection of tumor viability after radiofrequency and microwave
ablation therapy of hepatocellular carcinoma.
Subjects and methods: The study was done on 50 patients with HCC underwent radiofrequency or
microwave ablation. Patients were classified into resolved group if there’s no MRI evidence of
tumor viability at the ablated lesion and unresolved group if there’s evidence of tumor viability.
Results: In the early 1 month post-ablation period, heterogenous signal of the ablation zone in the
precontrast T1 and T2 images was noted that gradually become more homogenous in the 3–
12 months follow-up. Ill defined persistent perilesional enhancement is considered as a benign find-
ing that was present in 100% of patients imaged within the 1st month and persists only in 5% after
9–12 months. The mean ADC value of the malignant lesions was 0.91 ± 0.09  103 mm2/s, while
the mean ADC value of the benign post-ablation parenchymal changes was 1.29
± 0.12  103 mm2/s with a cutoff value of 1.05  103 mm2/s.
Conclusion: MRI provides a powerful tool in the assessment of treatment response after RFA and
MWA of hepatocellular carcinoma.
 2016 The Egyptian Society of Radiology andNuclearMedicine. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
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Hepatocellular carcinoma (HCC) is one of the most common
cancers worldwide, and has a poor prognosis unless treated.
Generally, surgical resection is the gold standard therapy for
HCC. Another treatment option is liver transplantation which
is theoretically the best treatment for HCC. Currently, ablative
therapies are alternative choice for patients with liver tumors
who are not eligible for surgery (1). Thermal ablation is
achieved by using heat (radiofrequency ablation, microwave
ablation, laser ablation) or cold (cryoablation). Among all
the ablative techniques, RF ablation is the one of the most
widely used for both primary and secondary malignances of
the liver, but all hyperthermal techniques produce coagulation
necrosis, and demonstrate similar imaging features on follow-
up studies (2).
Monitoring tumor response to locoregional therapy is an
increasingly important task in oncologic imaging. Early favor-
able response generally indicates effectiveness of therapy, and
may result in significant survival benefit. Early identification of
treatment failure is also critical in patient management, since a
repeat treatment cycle can be performed if liver function is
maintained, before disease progression occurs. CT and MRI
have been used to depict hepatic lesions, to guide the interven-
tion process, and to evaluate the response of malignant liver
lesions after minimally invasive local therapies. MRI has been
described as superior to CT in detecting and following up
ablated lesions because of its known higher sensitivity and
specificity (3).
Recent advances in the development of functional imaging
techniques have provided the ability to detect microscopic
changes in tumor microenvironment and microstructure, thus
allowing the assessment of tumor response after locoregional
treatment by observing alterations in tumor viability, perfu-
sion or vascularity. Diffusion weighted MR imaging is useful
in the follow-up imaging after RF ablation. ADC-based eval-
uation of signal alterations adjacent to the ablation zone may
contribute to the identification of local tumor progression and
nontumoral post-treatment tissue changes (4,5).
2. Subjects and methods
2.1. Patients
This study included 50 HCC lesions in 50 patients underwent
radiofrequency or microwave ablation over a period of
21 months (July 2012–March 2014). 35 patients underwent
radiofrequency ablation and 15 patients underwent microwave
ablation. The patients’ ages ranged between 45 and 81 years
(mean age 60); 42 patients were males and 8 patients were
females. All patients had liver cirrhosis related to chronic viral
hepatitis. Written consents were obtained from all patients.
Exclusion criteria include tumors other than hepatocellular
carcinoma and contraindications to magnetic resonance imag-
ing, e.g. claustrophobia and cardiac pacemakers.2.2. Post-procedural MR imaging
Patients were scheduled to undergo MRI within 1 month after
ablation. If there is no evidence of residual/recurrent lesions,follow-up was arranged to be after 3 months from the first
MRI and then every 6 months for the first two years after abla-
tion. In our study 30 patients were examined 1 month after the
ablation, 33 patients within 4–6 months and 20 patients within
9–12 months after ablation. The variability of time was related
to clinical practice and does not affect our results.
MRI was performed using Philips 1.5 Tesla MRI scanner
(Achieva). Precontrast sequences were axial T1, T2 and
SPAIR, coronal T1 and T2 and Diffusion imaging. Diffusion
imaging was performed before the dynamic study using respi-
ratory triggered fat suppressed single-shot spin echo echopla-
nar sequence. It was obtained by applying three different b
values of 0, 500, and 1000 s/mm2. Dynamic study was then
performed after manual bolus injection of 0.1 mmol/kg body
weight of Gd-DTPA, flushed with 20 ml of sterile saline solu-
tion via the antecubital vein. Dynamic imaging was done using
3D GRE T1 sequence (THRIVE = T1 High Resolution Iso-
tropic Volume Examination). A dynamic study consisted of
one precontrast series followed by four successive post-
contrast series including multi arterial and portal phases with
19–21 s intervals (17 s for image acquisition with breath-
holding and 2–4 s for re-breathing) and this is followed by 5-
min delayed phase imaging. All patients were imaged in end
expiration to limit the risk of image misregistration. Acquisi-
tion parameters of the dynamic study were TR 4.4 ms, TE
2.1 ms, flip angle 10, matrix size, 172  163, field of view
300–350 mm and slice thickness 2–3 mm.
2.3. Imaging analysis and interpretation
Magnetic resonance images were analyzed using the available
workstation (Phillips Extended MR Workspace, 2.6.3.5
Netherlands) by two abdominal radiologists reading indepen-
dently. The readers had experience of 5 and 12 years in abdom-
inal MR imaging.
The morphological features of the ablation zone studied
include size, border and signal intensity at T1 and T2 images
that were classified as high, low or heterogenous. Dynamic
study analysis: Arterial and portal phase dynamic subtraction
was performed which is automated process available on the
workstation. Subtraction color coded mapping is then per-
formed. Pattern of enhancement in the dynamic imaging, sub-
tracted images and color mapping was then studied.
Quantitative diffusion analysis (ADC measurement): ADC
maps were generated on the workstation. ADC was calculated
with linear regression analysis of the function S= S0  exp
(b  ADC), where S is the signal intensity after application
of the diffusion gradient, and S0 is the signal intensity at a b
value of 0 s/mm2. The three b values were used for ADC calcu-
lation. The ROI included the entire ablation zone. Another
area of 2 cm diameter in the cirrhotic liver parenchyma was
also measured in each case as a control. In case of focal hyper-
intensity within or at the margins of the ablation zone that sus-
pects recurrence, its ADC value was calculated.
2.3.1. Dynamic study interpretation
Arterial phase enhancement: it should be confirmed by the sub-
traction images and color map (to prove that the high signal in
the arterial phase is due to enhancement and not due to the
original precontrast high T1 signal). Contrast washout:
Decrease in the enhancement on delayed phase imaging when
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ilesional parenchymal enhancement that represents post-
interventional reactive changes: this is defined as early phase
enhancement beyond the ablation zone on the surrounding
liver parenchyma that persists or becomes homogenous to
the enhancing liver parenchyma in the delayed phase. Perfu-
sion changes may occur in cases of injury of the portal vein
or traumatic arterio-portal shunting.Well defined enhancement
at the margin of the ablation zone represents either granulation
tissue or recurrent neoplastic lesion. The granulation tissue will
appear as thin rim with persistent or delayed phase enhance-
ment, while recurrent or residual neoplastic lesion will show
nodular or hallow enhancement during the arterial phase with
delayed washout.Fig. 1 (A) Signal intensity of the ablation zone in the T2 images.
(B) Signal intensity of the ablation zone in the T1 weighted images.2.4. Statistical analysis
 Descriptive analysis was done and results are expressed as
mean ± standard deviation or number (%).
 Comparison between mean values of ADC in the studied
groups was performed using unpaired t test.
 P value less or equal to 0.05 was considered significant and
less than 0.01 was considered highly significant.
2.5. The standard of reference
It was difficult to obtain pathologic confirmation in most cases
because most of the patients do not undergo surgery. In addi-
tion, biopsy may result in sampling error due to technical dif-
ficulties. So, the standard of reference was as follows:
Benign findings (resolved lesions) are considered if the find-
ings regress or disappear in the follow-up studies
Residual/recurrent HCC (unresolved lesions) is considered if:
 Increase in the size of the ablation zone when comparing
the images obtained <4 months after treatment with t-
hose obtained 4–6 and >6 months after treatment.
 Focal area at the margin of the ablation zone shows e-
arly or late arterial phase enhancement that must be p-
roved by the subtraction and color map images and
contrast washout where drop of signal occurred in the
delayed phase. Diffusion restriction is also considered as
a sign of recurrence in the presence of positive dynamic
findings.
3. Results
The signal intensity of the entire ablation zone in the non-
enhanced T1 and in the T2 weighted images was studied
(Fig. 1) and we found that 66.6% of the patients imaged within
the 1st month after ablation show heterogenous high T1 and
low T2 signal, 20% show homogenous high T1 and low T2 sig-
nal and 13.3% show homogenous low T1 and high T2 signal.
While in the 4–12 months imaging most of the ablation zones
elicits homogenous high T1 and low T2 signal (78.7% of
patients imaged within 4–6 months and 80% of patients
imaged within 9–12 months).There was no significant statistical difference in the signal
intensity of the entire ablation zone between the resolved
and unresolved groups or between the microwave and
radiofrequency ablated lesions.
37 patients (74%) have resolved lesions while 13 patients
(26%) have recurrent or residual tumor viability. The types
of the tumor recurrence were studied and we followed the clas-
sification of Chopra et al. (6) and we found that nodular type
was the most common and detected in 76.9% of cases followed
by the halo type and the gross enlargement type those detected
in 7.7% for each. More than one type of recurrence was seen in
one patient (7.7%) where there were nodular and halo recur-
rence (Fig. 2).
We also studied the signal intensity of the recurrent lesions
in the unenhanced T1, T2 and diffusion weighted images and
we classified the signal intensity of the lesion into intermediate,
high or low signal (relative to the ablation zone). We found
77% of the recurrent lesions elicit high T2 signal and only
31% of the lesions elicit low T1 signal. This shows that T2
weighted images is superior to non-enhanced T1 weighted
images in detection of tumor recurrence.
We classified the signal intensity of the recurrent/residual
lesion in the diffusion weighted images at b values 1000 into
two types: intermediate or high signal (relative to the signal
of the ablation zone). 12 out of 13 lesions elicit high signal
and 1 lesion elicits intermediate signal. In the lesion with inter-
mediate signal in the diffusion images, the dynamic study
detected the lesion and this was proved by PET-CT.
We studied the presence of ill defined perilesional enhance-
ment. It was found to be a benign finding (based on the follow-
up study) that represents reactive inflammatory and vascular
changes of the liver parenchyma adjacent to the ablation zone.
Fig. 2 58 years old male imaged 4 months after microwave ablation of right hepatic lobe hepatocellular carcinoma. (a and b) Axial T1
and T2 WIs. The ablation zone shows central area of coagulation necrosis eliciting high T1 and low T2 signal (red arrows) with a small
nodule (white arrows) and thick halo (yellow arrow) at its margins. (c) Diffusion WIs and (d) ADC map at the same levels show restricted
diffusion of the small nodule (nodular type of recurrence) and the thick rim (halo type of recurrence) in contrast to the center of the lesion
that shows free diffusion. (e and f) Late arterial phase subtracted images. The enhancement of the nodule and halo at the margin of the
ablation zone becomes more evident in the late arterial phase. Also this appears more obvious at the color map images (g) where the
ablation zone (red arrows) appears non-enhancing relative to the liver while the recurrent tumor at the margin of the lesion shows intense
enhancement (white arrows).
380 B.E.M.H. Mahmoud et al.These areas exhibit mild hyperintensity in the diffusion imag-
ing. This was present in 100% of patients imaged within the
1st month after ablation. This persists in 9% of patients
imaged at 4–6 months and only in 5% after 9–12 months.
The presence of well defined thin rim of marginal enhance-
ment was also studied. This was present in 93% of patients
imaged within the 1st month after ablation, 81% in patients
imaged at 4–6 months after ablation and 45% in patients
imaged 9–12 months after the ablation.
The ADC values of the entire ablation zones, suspected
recurrent lesions, surrounding post-ablation parenchymal
changes and cirrhotic liver were calculated for the different
study groups (table 1) and we found that the mean ADC value
of the entire ablation zone in the RF ablated lesions (whether
resolved or non-resolved) was 1.38 ± 0.19  103 mm2/s while
for the microwave ablated lesions it was 1.30
± 0.16  103 mm2/s. We found the mean ADC value of theTable 1 Mean ADC values of cirrhotic liver parenchyma, entire ab
Category No. Minim
Cirrhotic parenchyma 50 0.99
Entire ablation zone in RF ablated lesions 35 1.11
Entire ablation zone in MW ablated lesions 15 1.01
Malignant lesions 13 0.74
Reactive tissue changes 30 0.98recurrent or residual lesions in the malignant group (whether
post-RFA or MWA) was 0.91 ± 0.09  103 mm2/s while
the mean ADC value of the surrounding benign post-
ablation parenchymal changes was 1.29 ± 0.12  103 mm2/
s. The ADC value of the cirrhotic parenchyma was also mea-
sured as a control and ranged from 0.99 to 1.32  103 mm2/s
(mean 1.18 ± 0.07).
Then comparison between different study groups was done
(table 2) and we found that the mean ADC value of the entire
ablation zones was significantly higher than mean ADC of the
cirrhotic liver parenchyma (p value 0.0001). The mean ADC
value of the recurrent lesions was significantly lower than the
mean ADC of the entire ablation zones (p value 0.0001). The
mean ADC value of the recurrent lesions was significantly
lower than the mean ADC of the cirrhotic liver parenchyma
(p value 0.0001). The mean ADC value of the post-treatment
benign reactive tissue changes was significantly higher thanlation zone, malignant lesions and reactive tissue changes.






Table 2 Comparison between the mean ADC values of the study groups.
Entire ablation zones in all patients (n= 50) Cirrhotic parenchyma in all patients (n= 50) ADC ratio P value
1.36 ± 0.18 1.18 ± 0.07 1.15 0.0001**
Residual malignant or recurrent lesions (n= 13) Entire ablation zones in all patients (n= 50) ADC ratio P value
0.91 ± 0.09 1.36 ± 0.18 0.66 0.0001**
Residual malignant or recurrent lesions (n= 13) Cirrhotic parenchyma in all patients (n= 50) ADC ratio P value
0.91 ± 0.09 1.18 ± 0.07 0.77 0.0001**
Residual malignant or recurrent lesions (n= 13) Post-treatment parenchymal changes (n= 30) ADC ratio P value
0.91 ± 0.09 1.29 ± 0.12 0.70 0.0001**
Entire ablation zone post RF (n= 35) Entire ablation zone post-MW (n= 15) P value
1.38 ± 0.19 1.30 ± 0.16 0.16
Entire ablation zones in the benign group (n= 37) Entire ablation zones in the malignant group (n= 13) P value
1.37 ± 0.20 1.39 ± 0.09 0.7
Fig. 3 (a–c) Axial T1, T2 and SPAIR obtained 1 month after microwave ablation of left hepatic lobe HCC in a 54 years old male
patient. The ablation zone in the left hepatic lobe elicits high T1 and low T2 and SPAIR signal with peripheral thin rim of low T1 and high
T2 signal. (d–f) Axial T1, T2 and SPAIR obtained 4 months after the 1st MRI show that the ablation zone had regressed in size and
became of more homogenous signal. (g) Axial arterial phase and (h) axial delayed phase images. The ablation zone appears of high signal
in the arterial phase and low signal in the delayed phase, however this is not due to arterial enhancement and delayed washout, but this is
due to drop of the signal of the non-enhancing ablation zone relative to the progressively enhancing liver parenchyma. This is proved by
the subtracted arterial phase image (i) and the color map image (j) where the lesion appears blue (in the lowest part of the color scale).
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382 B.E.M.H. Mahmoud et al.the mean ADC of the recurrent or residual malignant lesions
(p value 0.0001). There was no statistical difference in the mean
ADC values between the entire ablation zones of the resolved
and unresolved groups (p value 0.70) and between the entire
ablation zone of the microwave and radiofrequency treated
lesions (p value 0.16).Fig. 4 Axial T1 dynamic study obtained one month (a–c) and 9 mon
carcinoma in 63 year old male. No enhancement noted within the ablat
enhancement in the early follow-up MRI (white arrows) almost totall
Fig. 5 Axial delayed phase image obtained 5 min after contrast ad
ablation of segment VIII hepatocellular carcinoma in 56 years old m
peripheral rim.4. Discussion
Our study was performed to assess the role of dynamic con-
trast enhanced and diffusion MR imaging in the assessment
of treatment response and detection of tumor viability afterths (d–f) after radiofrequency ablation of right lobe hepatocellular
ion zone or at its margins. The surrounding persistent parenchymal
y disappeared in the late follow-up study.
ministration (a) one month after ablation and (b) 6 months after
ale patient. Note the regression in the thickness of the enhancing
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lular carcinoma.
The heterogenous signal of the ablation zone in the non-
enhanced T1 and in the T2 images in the early post-ablation
imaging could be explained by the different tissue changes
after ablation including edema, hemorrhage and inflammatory
reaction. Such changes are mostly resolved within 4–6 months
after ablation leaving only the coagulation necrosis with the
characteristic homogenous high T1 and low T2 signal
(Fig. 3). Kierans et al. (3) performed a study over 203 ablated
lesions for which MRI was acquired after radiofrequency abla-
tion, cryoablation, and microwave ablation. They found that
87.8% of the RF ablation zones imaged within the first
4 months after ablation show high T1 signal with persistence
of the high signal in about 84.1% in patients imaged
>9 months after ablation.
The absence of significant difference in the signal intensity
of the entire ablation zone between the resolved and unre-
solved groups at the early imaging follow-up could be
explained by the fact that the recurrence is mostly at the mar-
gin of the ablation zone. This also may be contributed to the
post-treatment reactive changes that occur within the ablationFig. 6 (a and b) Axial diffusion weighted images (b 1000) and corres
the dynamic study and (e) subtracted arterial phase image obtained 3 m
patient. There are multiple nodules (red arrows) and those show arter
restriction and low ADC values denoting recurrent HCC in contrast to
mild diffusion hyperintensity (yellow arrows) with no corresponding a
dynamic study is partially degraded by respiratory motion artifact h
lesions.zone which may mask any recurrent lesions within the center
of the ablation zone (5).
T2 is superior to T1 in detection of recurrent lesions; this
could be explained by the higher contrast between the low sig-
nal ablation zone and the high signal of the lesion. However at
early post-ablation follow-up, the heterogenous T2 signal may
mask tumor recurrence, so we cannot depend on T2 signal
alone in the early follow-up imaging and correlation with the
dynamic study findings is essential in the assessment of the
treatment response.
The ill defined perilesional enhancement is found to be a
benign finding based on the follow-up study that represents
reactive inflammatory and vascular changes of the liver par-
enchyma adjacent to the ablation zone and this should regress
and disappear over time (Fig. 4). With residual or recurrence
of the tumor, the area of contrast enhancement is irregular,
nodular and thicker and shows contrast washout in the
delayed phase (7).
A thin rim surrounding the necrotic cavity can be seen. This
rim has low signal intensity on T1, and high signal intensity on
T2 images with persistent or delayed post-contrast enhance-
ment and mild diffusion hyperintensity. The histologic analysisponding ADC map. (c and d) Axial arterial and delayed phases of
onths after radiofrequency ablation of HCC in a 59 year old male
ial enhancement and delayed washout. Note the marked diffusion
the surrounding ill defined parenchymal enhancement that shows
reas of low ADC values. Unfortunately the arterial phase of the
owever, the diffusion images proved the recurrence of neoplastic
384 B.E.M.H. Mahmoud et al.of the perilesional rim reveals a vascularized inflammatory
reaction, hemorrhage, and granulation tissue (8). This periph-
eral rim most often measures 1–2 mm, but can measure up to
5 mm, and regresses progressively (Fig. 5).
Liquefactive necrosis partly or completely consists of fluid
remnants of tissue that became necrotic and was digested by
enzymes. Because of the fluid content, liquefactive necrosis
appears hyperintense on T2 images (9).4.1. Role of subtraction technique
The detection of enhancement within the ablation zone is chal-
lenging because of the precontrast high T1 signal of the coag-
ulation necrosis. In the early arterial phase the liver
parenchyma is mildly enhancing; thus, the ablation zone may
preserve its high T1 signal relative to the liver while in the sub-
sequent phases there’s progressive parenchymal enhancement,
so the non-enhancing ablation zone becomes hypointense rel-
ative to the liver that could be misinterpreted as pathologic
arterial enhancement and subsequent washout. To solve thisFig. 7 54 year old male patient after MWA of hepatic focal lesion at
zone (red arrow) eliciting high T1 signal. A large nodule is seen along t
(yellow arrow). (b) Subtracted arterial phase image and (c) axial arteri
nodule without enhancement of the ablation zone (denoting recurrent
map at the same level show restricted diffusion of the malignant nod
(arrow heads) that appear of high signal in the diffusion images wi
cellularity of the benign changes.problem, dynamic subtraction technique is performed whereby
corresponding contrast-enhanced and unenhanced T1-
weighted sequences are digitally subtracted image-by-image
using the MRI software. The objective of this process is to
remove pre-existing T1-weighted high signal from the post-
processed images so that the remaining high signal is solely
due to enhancement (Figs. 2 and 3). Subtraction MRI
improves reader confidence in detecting enhancement in abla-
tion zone and thus improves the overall MRI assessment of the
treatment response following locoregional therapy (10). It is
essential that the patient’s position remains unchanged within
the magnet during the unenhanced and contrast enhanced
sequences. The patient should be able to maintain a breath-
hold throughout the acquisition, and the breath-hold should
be reproducible from sequence to sequence. Not fulfilling
one or more of these criteria will result in misregistration arti-
fact and image degradation on the subtraction series (11). Sev-
eral solutions are described to overcome this artifact including
imaging at end expiration, image by image subtraction by
choosing the images that will be subtracted manually instead
of subtracting the whole series and post-processing softwaresegment VIII (a) Coronal T1 weighted images shows the ablation
he anteroinferior margin of the ablation zone elicting low T1 signal
al phase image without subtraction show avid enhancement of the
HCC). (d) Diffusion weighted images (b value 800) and (e) ADC
ule (yellow arrows). Note the surrounding parenchymal changes
th no signal drop in the corresponding ADC map denoting low
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performing registration correction on the source data (10).
Precise and accurate arterial phase timing is critical to hep-
atic lesion detection and characterization. The optimal time to
capture arterially enhancing lesions of the liver is slightly later
than the time at which the aorta and hepatic artery enhance-
ment peaks (12). The use of multi arterial phase imaging rather
than fixed time delay is recommended to ensure that at least
one of the phases will capture the lesion at its time of maxi-
mum enhancement.
The diffusion analysis revealed significant statistical differ-
ence between the therapeutically induced non-tumoral tissue
changes (edema, inflammation, fibrosis and necrosis) and the
malignant lesions and we detect a cutoff value of
1.05  103 mm2/s. This is explained by the fact that benign
tissue changes usually show low cellularity and therefore pre-
sent with less signal in DWI and high ADC value, and can
thereby be distinguished from tumoral tissue that presents with
high signal in DWI and low ADC value (Figs. 6 and 7) (5).
To our knowledge, the largest study on the role of the dif-
fusion imaging post-radiofrequency ablation was done by
Schraml et al. (5) who studied 148 follow-up MR examinations
of 54 patients after RFA of malignant focal lesions. They
detected mean ADC values of the entire ablation 1.19
± 0.30  103 mm2/s while for the liver parenchyma it was
1.06 ± 0.21  103 mm2/s (P value 0.0003). They found that
ADC values obtained from the entire ablation zones did not
significantly differ between the resolved group (1.22
± 0.30  103 mm2/s) and the unresolved groups (1.19
± 0.30  103 mm2/s). They also found that the mean ADC
value of the recurrent lesions differs significantly from the
mean ADC value of the surrounding parenchymal tissue
changes (P value 0.0124). Their results agreed with our results.
4.2. Limitations
Limitations of this study include various time intervals
between interventions and follow-up studies, which were deter-
mined by clinical practice and not the study design. A further
limitation is the lack of histologic proof in most cases, but this
is also related to clinical practice where histology is not always
indicated.
The measurement of the ADC of the entire ablation zone is
not accurate in detection of the recurrent lesion within the cen-
ter of the ablation zone as it could be masked by the post-
ablation changes, however the fact that most of the recurrence
occur at the periphery of the ablation zone rather that within
its center should be considered. Another limitation in diffusion
analysis includes the absence of pre-interventional MRI in
most cases so we didn’t have the ADC before the treatment.
5. Conclusion
MRI is a powerful tool in the assessment of treatment response
and detection of tumor viability after RFA and MWA of hep-
atocellular carcinoma. Radiologists should be familiar with theimaging appearance of the normal ablation zones and benign
post-ablation changes in order to detect malignant lesions.
Imaging protocol should include dynamic study combined
with diffusion imaging with post-processing of the images to
obtain subtracted images and color mapping for better tissue
characterization and should be performed at regular time
intervals. Dynamic study is the cornerstone in detection of
recurrent lesions while ADC measurements can differentiate
between malignant lesions and post-treatment benign
parenchymal changes. Well defined nodular enhancement,
thick irregular marginal enhancement or gross enlargement
of the lesion with arterial phase enhancement and contrast
washout were considered positive for malignancy, while ill-
defined persistent enhancement or well defined rim marginal
enhancement is considered as benign post-ablation changes.
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